Kuiken, Hendrik J.
Dhakal, Sabin
Selfors, Laura M.
Friend, Chandler M.
Zhang, Tian
Callari, Maurizio
Schackmann, Ron C. J.
Gray, G. Kenneth
Crowdis, Jett
Bhang, Hyo-eun C.
Baslan, Timour
Stegmeier, Frank
Gygi, Steven P.
Caldas, Carlos http://orcid.org/0000-0003-3547-1489
Brugge, Joan S. http://orcid.org/0000-0002-2547-4814
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P01CA080111, P01CA080111, P01CA080111, P01CA080111, P01CA080111)
Breast Cancer Research Foundation (BCRF-19-021, BCRF-19-021, BCRF-19-021, BCRF-19-021, BCRF-19-021)
Ludwig Center at Harvard
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 7 March 2021
Revised: 1 October 2021
Accepted: 11 October 2021
First Online: 26 October 2021
Competing interests
: JSB is a consultant for Agios Pharmaceuticals, eFFECTOR Therapeutics, and Frontier Medicines. The other authors declare no conflict of interest.